In this video, Motley Fool health care analyst David Williamson takes us through some of the biggest investing stories in the health care space yesterday. He tells us about Ligand's (NASDAQ:LGND) big FDA win -- and why its relevance may be very short-lived -- and how AVEO Pharmaceuticals (NASDAQ:AVEO) is bouncing back after taking a big hit last week and what's ahead for the company. He also discusses how pharmaceutical giant Pfizer (NYSE:PFE) doesn't always get what it wants.
Motley Fool Returns
Discounted offers are only available to new members. Stock Advisor will renew at the then current list price. Stock Advisor list price is $199 per year.
Stock Advisor launched in February of 2002. Returns as of 12/08/2021.
Average returns of all recommendations since inception. Cost basis and return based on previous market day close.